Abstract: A lubricating composition comprises an amide and at least one additive. The amide is the reaction product of a secondary, branched amine and a carboxylic acid. The carboxylic acid may be a monocarboxylic acid or a dicarboxylic acid, including dimer acid. The amide is hydrolytically stable, and may be used to increase the hydrolytic stability of the lubricant composition. Alternatively, the amide may be used to increase the additive solubility or detergency of the lubricant composition.

Abstract: Provided is a method of dispersing asphaltenes to inhibit asphaltene precipitation and/or deposition in a hydrocarbon. The method includes adding to the hydrocarbon an asphaltene dispersing agent which is an ester of a mono-carboxylic fatty acid and a sugar. The sugar has at least 4 hydroxyl groups. In addition, more than one of the hydroxyl groups on the sugar are reacted with the mono-carboxylic fatty acid to form the ester.

Abstract: A method of dispersing asphaltenes to inhibit asphaltenes precipitation and/or deposition in a hydrocarbon is disclosed. An asphaltene dispersing agent is added to the hydrocarbon. The asphaltene dispersing agent is an ester of a mono-carboxylic fatty acid and a sugar. The sugar has at least 4 hydroxyl groups and more than one of the hydroxyl groups on the sugar are reacted with the mono-carboxylic fatty acid to form the ester. A composition comprising the asphaltene dispersing agent is also disclosed.

Abstract: A lubricating composition comprises an amide and at least one additive. The amide is the reaction product of a secondary, branched amine and a carboxylic acid. The carboxylic acid may be a monocarboxylic acid or a dicarboxylic acid, including dimer acid. The amide is hydrolytically stable, and may be used to increase the hydrolytic stability of the lubricant composition. Alternatively, the amide may be used to increase the additive solubility or detergency of the lubricant composition.

Abstract: The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I?): wherein R1-R16, Ra, Rb, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I?).

Abstract: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1A receptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

Abstract: The present invention relates to novel metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline, which can be useful in treating CNS disorders. The present invention further relates to processes for their preparation, to pharmaceutical compositions comprising them, and to methods of using them.

Abstract: 3-Amino chroman and 2-amino tetralin derivatives and compositions containing such compounds are disclosed. Such compounds are useful for modulating activity of a 5-HT1A receptor (agonizing or antagonizing) in a patient. These compounds are further useful for inhibiting binding to a serotonin receptor. Methods of using the 3-amino chroman and 2-amino tetralin compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety, are also disclosed.

Abstract: The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.